Aficamten shows positive Phase 3 results improving symptoms and exercise in non-obstructive hypertrophic cardiomyopathy.

Cytokinetics announced positive topline results from the ACACIA-HCM Phase 3 trial, where aficamten significantly improved symptoms and exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy (HCM). The trial met both primary endpoints, showing better Kansas City Cardiomyopathy Questionnaire scores and maximal exercise performance compared to placebo. Secondary endpoints also showed improvements, with no new safety concerns. These results mark a potential first approved therapy for non-obstructive HCM, with further regulatory discussions and presentations planned.